Published in J Heart Lung Transplant on May 08, 2011
A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ (2013) 0.94
Endothelin-1 induces a glycolytic switch in pulmonary arterial endothelial cells via the mitochondrial translocation of endothelial nitric oxide synthase. Am J Respir Cell Mol Biol (2014) 0.90
The interaction of endothelin-1 and TGF-β1 mediates vascular cell remodeling. PLoS One (2013) 0.81
Determination of the effects of pulmonary arterial hypertension and therapy on the cardiovascular system of rats by impedance cardiography. Croat Med J (2014) 0.77
PKC δ and βII regulate angiotensin II-mediated fibrosis through p38: a mechanism of RV fibrosis in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2015) 0.76
Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement? Heart Fail Rev (2015) 0.76
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension. J Cardiovasc Pharmacol (2015) 0.75
NS1619-induced vasodilation is enhanced and differentially mediated in chronically hypoxic lungs. Lung (2014) 0.75
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest (2004) 7.91
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
Structural basis of protein kinase C isoform function. Physiol Rev (2008) 4.00
The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med (1979) 3.87
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol (2009) 3.64
Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A (1992) 2.48
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther (1994) 2.14
The endothelin system in pulmonary arterial hypertension. Cardiovasc Res (2004) 2.09
Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes. Possible role of protein kinase C activation. J Biol Chem (1991) 1.60
Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol (1988) 1.57
Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest (1993) 1.51
Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res (2000) 1.37
Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol (1985) (1995) 1.22
Signalling pathways in cardiac myocyte hypertrophy. Ann Med (2001) 1.18
Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem Biophys Res Commun (2004) 1.00
Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest (1998) 1.00
Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem (2004) 0.96
Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells. Toxicol Appl Pharmacol (1998) 0.95
Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol Respir Environ Exerc Physiol (1983) 0.95
Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol (2000) 0.94
Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes. Cardiovasc Res (2003) 0.93
A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc (2006) 0.92
Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol (1985) (1997) 0.92
Regulation of protein kinase C delta by phorbol ester, endothelin-1, and platelet-derived growth factor in cardiac myocytes. J Biol Chem (2005) 0.91
Endothelin-dependent actions in cultured AT-1 cardiac myocytes. The role of the epsilon isoform of protein kinase C. Circ Res (1996) 0.88
Molecular biology of cardiac growth and hypertrophy. Herz (1993) 0.85
Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts. J Mol Cell Cardiol (2009) 0.83
Protein kinase C mRNA and protein expressions in hypobaric hypoxia-induced cardiac hypertrophy in rats. Acta Physiol (Oxf) (2009) 0.83
Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol (1993) 0.82
Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: evidence for two distinct mechanisms for endothelin regulation. J Pharmacol Exp Ther (2004) 0.82
Contractile potentiation by endothelin-1 involves protein kinase C-delta activity in the porcine coronary artery. Jpn J Physiol (1999) 0.81
Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms. Mol Cell Biochem (2006) 0.80
Hypoxic inhibition of human cardiac fibroblast invasion and MMP-2 activation may impair adaptive myocardial remodelling. Biochem Soc Trans (2007) 0.79
Evidence for altered ETB receptor characteristics during development and progression of ventricular cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol (2004) 0.77
Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol (2007) 1.91
Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med (2005) 1.75
Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J (2013) 1.61
Successful determination of lower inflection point and maximal compliance in a population of patients with acute respiratory distress syndrome. Crit Care Med (2002) 1.60
Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice. Cardiovasc Res (2013) 1.60
Ethics and economics: does programme budgeting and marginal analysis contribute to fair priority setting? J Health Serv Res Policy (2006) 1.52
Conventional protein kinase C mediates phorbol-dibutyrate-induced cytoskeletal remodeling in a7r5 smooth muscle cells. Exp Cell Res (2002) 1.40
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. Can J Clin Pharmacol (2009) 1.30
Transforming growth factor-beta1-induced endothelial barrier dysfunction involves Smad2-dependent p38 activation and subsequent RhoA activation. J Appl Physiol (1985) (2006) 1.18
Isoprenylcysteine carboxyl methyltransferase modulates endothelial monolayer permeability: involvement of RhoA carboxyl methylation. Circ Res (2003) 1.07
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther (2009) 1.05
Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. Exp Cell Res (2006) 1.04
Advanced biological and chemical discovery (ABCD): centralizing discovery knowledge in an inherently decentralized world. J Chem Inf Model (2007) 1.04
The right ventricle in sepsis. Clin Chest Med (2008) 1.03
Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest (2006) 1.02
Rottlerin causes pulmonary edema in vivo: a possible role for PKCdelta. J Appl Physiol (1985) (2007) 1.01
Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis. Mol Biol Cell (2003) 0.99
Adenosine protected against pulmonary edema through transporter- and receptor A2-mediated endothelial barrier enhancement. Am J Physiol Lung Cell Mol Physiol (2010) 0.99
Using serial severity scores to predict death in ICU patients: a validation study and review of the literature. Curr Opin Crit Care (2009) 0.99
Apoptosis and lung injury. Keio J Med (2005) 0.97
Transforming growth factor-beta1 causes pulmonary microvascular endothelial cell apoptosis via ALK5. Am J Physiol Lung Cell Mol Physiol (2009) 0.96
Genetic disruption of protein kinase Cδ reduces endotoxin-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2012) 0.95
Pulmonary arterial hypertension: new insights and new hope. Respirology (2006) 0.94
Partial anomalous pulmonary venous return presenting with adult-onset pulmonary hypertension. Pulm Circ (2012) 0.93
Cigarette smoke causes lung vascular barrier dysfunction via oxidative stress-mediated inhibition of RhoA and focal adhesion kinase. Am J Physiol Lung Cell Mol Physiol (2011) 0.93
Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome. Chest (2002) 0.92
FAK blunts adenosine-homocysteine-induced endothelial cell apoptosis: requirement for PI 3-kinase. Am J Physiol Lung Cell Mol Physiol (2002) 0.92
Pulmonary hypertension in the intensive care unit: Critical role of the right ventricle. Crit Care Med (2007) 0.91
Executive functioning and imitation: Increasing working memory load facilitates behavioural imitation. Neuropsychologia (2009) 0.91
Priority-setting for healthcare: who, how, and is it fair? Health Policy (2007) 0.89
Protection against LPS-induced pulmonary edema through the attenuation of protein tyrosine phosphatase-1B oxidation. Am J Respir Cell Mol Biol (2011) 0.88
Pulmonary hypertension in a stable community-based COPD population. Lung (2011) 0.87
Diagnosis and management of pulmonary arterial hypertension. Pulm Med (2011) 0.87
PKCdelta influences p190 phosphorylation and activity: events independent of PKCdelta-mediated regulation of endothelial cell stress fiber and focal adhesion formation and barrier function. Biochim Biophys Acta (2009) 0.86
The case for increased funding for research in pulmonary and critical care. Am J Respir Crit Care Med (2012) 0.86
Interplay between FAK, PKCδ, and p190RhoGAP in the regulation of endothelial barrier function. Microvasc Res (2011) 0.86
The lectin-like domain of complement receptor 3 protects endothelial barrier function from activated neutrophils. J Immunol (2004) 0.86
Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol (2005) 0.86
Management of acute right ventricular failure in the intensive care unit. Ann Am Thorac Soc (2014) 0.86
Marrow cell infusion attenuates vascular remodeling in a murine model of monocrotaline-induced pulmonary hypertension. Stem Cells Dev (2009) 0.85
Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood) (2004) 0.85
Mechanism of C-type natriuretic peptide-induced endothelial cell hyperpolarization. Am J Physiol Lung Cell Mol Physiol (2008) 0.84
Combination therapy for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis (2011) 0.83
Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy. Gynecol Oncol (2009) 0.82
Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emerg Med Australas (2013) 0.82
Inhibition of ICMT induces endothelial cell apoptosis through GRP94. Am J Respir Cell Mol Biol (2007) 0.81
A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant. Brachytherapy (2010) 0.81
Heterogeneity in apoptotic responses of microvascular endothelial cells to oxidative stress. J Cell Physiol (2012) 0.81
Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Devel Ther (2009) 0.79
C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade. Life Sci (2011) 0.79
Impact of endotracheal tube size on preextubation respiratory variables. J Crit Care (2010) 0.79
Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism. J Thromb Thrombolysis (2015) 0.79
WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Prog Cardiovasc Dis (2012) 0.78
Individual differences in (non-visual) processing style predict the face inversion effect. Cogn Sci (2012) 0.78
Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma. Int J Gynecol Cancer (2012) 0.78
SH2 domain-containing protein tyrosine phosphatase 2 and focal adhesion kinase protein interactions regulate pulmonary endothelium barrier function. Am J Respir Cell Mol Biol (2015) 0.78
Cardiac atria are the primary source of ANP release in hypoxia-adapted rats. Life Sci (2010) 0.77
Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A. J Appl Physiol (1985) (2012) 0.77
Pulmonary endothelial cell signaling and function. Trans Am Clin Climatol Assoc (2008) 0.77
Fractionated grid therapy in treating cervical cancers: conventional fractionation or hypofractionation? Int J Radiat Oncol Biol Phys (2007) 0.77
The bi-pedal ape: plasticity and asymmetry in footedness. Cortex (2008) 0.76
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Clin Chest Med (2013) 0.76
Explicit mentalizing mechanisms and their adaptive role in memory conformity. PLoS One (2013) 0.75
NO: more than just a vasodilator in lung transplantation. Am J Respir Cell Mol Biol (2002) 0.75
Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. Ann Am Thorac Soc (2014) 0.75
Initial risk assessment for pulmonary hypertension in patients with COPD. Lung (2011) 0.75
Alterations in molecular chaperones and eIF2alpha during lung endothelial cell apoptosis. Am J Physiol Lung Cell Mol Physiol (2010) 0.75
Networking medical devices: Carilion Clinic addresses the challenge. Biomed Instrum Technol (2011) 0.75
Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. Blood Coagul Fibrinolysis (2017) 0.75
Covert judgements are sufficient to trigger subsequent task-switching costs. Psychol Res (2012) 0.75
Pulmonary puzzle. An unusual cause of chest pain. Diagnosis: Cor triatriatum sinistrum with secondary unilateral pulmonary venous hypertension and right lung hypoplasia. Thorax (2011) 0.75
Tumor imaging: radiation oncology perspective. Top Magn Reson Imaging (2006) 0.75